Why It Matters
IQVIA faces a fundamental challenge: navigating an increasingly fragmented regulatory environment where federal, state, and executive branch actors are simultaneously reshaping rules governing health data privacy, AI deployment, cybersecurity standards, and pharmaceutical pricing—the core pillars of the company’s business.
IQVIA’s competitive advantage depends on unrestricted access to health data for analytics and clinical research, yet Congress and the White House are moving in opposite directions on data governance. Senator Cassidy’s Health Information Privacy Reform Act would extend HIPAA-like protections to consumer health apps and wearables while the White House simultaneously pursues federal AI preemption to block state privacy laws—creating operational uncertainty.
Healthcare cybersecurity vulnerabilities remain acute, with over 80% of stolen health data coming from third-party vendors like IQVIA itself, triggering heightened vendor scrutiny. However, favorable congressional momentum on clinical data access and clinical trial modernization presents genuine growth opportunities.
By the Numbers
IQVIA Inc. paid Republic Consulting LLC $60,000 for fourth quarter 2025 federal lobbying services, marking another quarter in a seven-year lobbying presence. The company has invested $2.66 million across three firms since 2019.
Republic Consulting remains IQVIA’s longest-standing partner, receiving $1.68 million over 29 disclosures since January 2019. Atlas Crossing LLC collected $820,000 over 17 filings for clinical trials and FDA user fee work from January 2022 through October 2025, while Horizon Government Affairs earned $160,000 across 16 disclosures since April 2022 focused on clinical trials and drug pricing.
The Agenda
IQVIA Inc. has maintained consistent federal lobbying since 2019, focused on core business priorities. While the company’s Q4 2025 Republic Consulting summary filing contains no specific legislative details, IQVIA’s historical agenda reveals enduring priorities:
Health Data Policy: Monitoring federal rules governing health information use and protection as Congress debates expanded privacy frameworks and AI governance standards.
Clinical Trials and Real-World Data: Advocating on research oversight, modernization initiatives, and expanded access to Medicare claims data.
Pharmaceutical Regulation: Engaging on drug pricing transparency, supply chain integrity, and the Prescription Drug User Fee Act.
Healthcare Technology and AI: Focusing on cybersecurity standards and AI deployment in clinical settings amid growing federal regulatory interest.
Between The Lines
Congress is actively shaping policy around issues central to IQVIA’s business. The Healthcare Cybersecurity Act of 2025 is gaining committee traction, while the MIND Act of 2025 directs FTC study of neural and biometric data governance.
AI legislation is expanding with the HEAL-AI Act establishing grant programs for medical AI training and the Health Tech Investment Act seeking Medicare payment pathways for FDA-approved AI devices.
The Access to Claims Data Act would grant clinician-led registries Medicare claims access, while the Prescription Pricing for the People Act mandates FTC study of pharmacy benefit manager roles.
Competitive Landscape
IQVIA operates within a crowded lobbying environment. Oracle Corp. lobbies on healthcare IT, data privacy, and AI. Johnson & Johnson Services Inc. spent $1.52 million in fourth quarter 2024 on drug pricing and data privacy. UnitedHealth Group Inc. maintains engagement on data privacy and digital health, while Siemens Healthineers AG advocates on healthcare data privacy and AI.
The Bottom Line
IQVIA’s fourth quarter 2025 lobbying reflects sustained engagement in a rapidly evolving healthcare policy environment. With Congress actively considering legislation affecting data privacy, AI governance, and clinical research, IQVIA’s seven-year, $2.66 million investment demonstrates a methodical approach to protecting its data-driven business model amid intense competition from major healthcare and technology corporations.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article